John G. Ullman & Associates Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$3.69M |
| 2 |
Tompkins Financial
TMP
|
+$3.57M |
| 3 |
NetEase
NTES
|
+$1.96M |
| 4 |
American Tower
AMT
|
+$1.8M |
| 5 |
INST
Instructure Holdings, Inc.
INST
|
+$1.65M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$7.15M |
| 2 |
Emerson Electric
EMR
|
+$6.15M |
| 3 |
Equinor
EQNR
|
+$4.39M |
| 4 |
NRG Energy
NRG
|
+$2.72M |
| 5 |
Eversource Energy
ES
|
+$2.55M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.68% |
| 2 | Healthcare | 17.44% |
| 3 | Industrials | 15.98% |
| 4 | Utilities | 9.18% |
| 5 | Energy | 5.9% |
Similar funds
John G. Ullman & Associates's Q1 2024 Portfolio in Review
As of Q1 2024, John G. Ullman & Associates held 180 positions worth $652M, up 3.4% from $630M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
John G. Ullman & Associates withdrew a net $20M in Q1 2024, closing 6 positions and reducing 93 holdings. Its most notable exit was JPMorgan Chase, an estimated $7.15M position sold in full.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, John G. Ullman & Associates opened a new position in Jazz Pharmaceuticals worth $3.63M.
- John G. Ullman & Associates's largest Q1 2024 buy was Jazz Pharmaceuticals: 30,150 shares worth $3.63M.
- John G. Ullman & Associates added most to Tompkins Financial in Q1 2024, an estimated $3.57M increase.
- John G. Ullman & Associates's biggest Q1 2024 reduction was Emerson Electric, cutting an estimated $6.15M.
- John G. Ullman & Associates fully exited JPMorgan Chase in Q1 2024, selling an estimated $7.15M.
- John G. Ullman & Associates's ten largest holdings make up 32% of its $652M portfolio in Q1 2024.
- John G. Ullman & Associates opened 11 new positions and closed 6 in Q1 2024.
- John G. Ullman & Associates's portfolio value rose 3.4% quarter-over-quarter to $652M.
Based on John G. Ullman & Associates's 13F filing for Q1 2024, filed 6 May 2024.